Ray Dalio Ligand Pharmaceuticals Inc Transaction History
Bridgewater Associates, LP
- $23.8 Billion
- Q3 2025
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 1,288 shares of LGND stock, worth $258,707. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,288Holding current value
$258,707% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LGND
# of Institutions
342Shares Held
20.5MCall Options Held
19KPut Options Held
11.5K-
Black Rock Inc. New York, NY2.87MShares$577 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.08MShares$417 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.04MShares$209 Million0.09% of portfolio
-
Macquarie Group LTD Australia, C3752KShares$151 Million0.16% of portfolio
-
State Street Corp Boston, MA749KShares$151 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $3.39B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...